Multiple Myeloma
Conditions
Brief summary
This is a Phase 1a/1b, multicenter, open-label, two-part study in subjects with relapsed or refractory MM: * Phase 1a: single agent CWP232291. Dose-finding followed by cohort expansion at the maximum tolerated dose (MTD) or optimal dose as determined by the Safety Review Committee (SRC). * Phase 1b: CWP232291 in combination with lenalidomide and dexamethasone. Dose-finding followed by cohort expansion at the combination therapy MTD or optimal dose as determined by the SRC.
Interventions
DRUGPhase 1a: CWP232291
CWP232291 administered alone twice weekly every 4 weeks.
DRUGPhase 1b: CWP232291, Lenalidomide, Dexamethasone
CWP232291 administered twice weekly every 4 weeks. Lenalidomide and Dexamethasone administered per standard therapy.
Sponsors
JW Pharmaceutical
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Able to understand and then sign an informed consent form (ICF) prior to initiation of any study-specific procedure and treatment. 2. ≥ 18 years of age. 3. Confirmed measurable MM based on the following: * Serum M component (≥ 0.5 g/dL), or * Urine M protein ≥ 200 mg/24 hours), or * Serum immunoglobulin free light chains ≥ 10 mg/dL and abnormal serum immunoglobulin kappa/lambda free light chain ratio), or * Non-secretory disease measurable with bone marrow biopsy or radiography. 4. Failed 2 or more prior standard MM therapies, and \>100 days post autologous bone marrow transplant prior to first dose for transplanted subjects. Prior lenalidomide is permitted. 5. In the absence of rapidly progressing disease, the interval from prior treatment to time of study drug administration should be ≥ 2 weeks for cytotoxic agents or at least 5 half-lives for noncytotoxic agents. Persistent clinically significant toxicities from prior chemotherapy or radiotherapy must not be greater than Grade 1. 6. Eastern Cooperative Oncology Group (ECOG) performance score 0-2 (Appendix 3). 7. Adequate bone marrow function: * Absolute neutrophil count (ANC) ≥ 1000/mm3, independent of growth factor support; * Platelet count ≥ 75,000/mm3; * Hb ≥ 9 g/dL (independent of transfusions or erythropoiesis-stimulating agents \[ESA\]). 8. Adequate renal function: * Serum creatinine ≤ 2.5 mg/dL; * Creatinine clearance (CrCl) ≥ 60 mL/minute (Cockcroft-Gault). 9. Adequate hepatic function: * Total bilirubin \< 2.5 x upper limit of normal (ULN); direct bilirubin \< 2 x ULN for Gilbert's syndrome; * Alkaline phosphatase (AP) ≤ 2.5 x ULN, unless considered due to organ leukemic involvement; * Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤ 3 x ULN. 11\. Women of child-bearing potential (ie, women who are premenopausal or not surgically sterile): * Two effective forms of contraception (abstinence, intrauterine device, oral contraceptive, or double barrier device) from the time of informed consent and until at least 4 weeks after discontinuing study drugs, and * Negative serum or urine pregnancy tests during screening and then within 3 days prior to Day 1. 12. Sexually active men - effective contraceptive methods in subject and partner from the time of informed consent and until ≥ 4 weeks after discontinuing study drugs. 13. Able to adhere to the study visit schedule and other protocol requirements.
Exclusion criteria
1. Chemotherapy or immunotherapy \< 5 half-lives prior to screening. 2. Not recovered to Grade 1 from adverse effects of prior myeloma therapy or radiotherapy prior to screening. 3. Systemic corticosteroids \< 1 week prior to Day 1 in Phase 1a. Subjects may receive stable physiologic replacement doses of glucocorticoids (up to the equivalent of 10 mg daily prednisone) as maintenance therapy for adrenal insufficiency. 4. Uncontrolled intercurrent illness including infections and psychiatric illness/social situations that may limit compliance with protocol requirements or the evaluation of study drugs. 5. Active cardiovascular disease including myocardial infarction (MI) \< 6 months of screening, symptomatic coronary artery disease (CAD), arrhythmias, hypertension, or heart failure not controlled by medication. 6. History of deep venous thrombosis and pulmonary embolism (Phase 1b). 7. Anticoagulants \< 7 days prior to Day 1. Aspirin is permitted in Phase 1b per standard of care with lenalidomide-based therapy. 8. Active central nervous system (CNS) disease. 9. Known positive status for human immunodeficiency virus (HIV) and/or active hepatitis B or C. 10. Pregnant or nursing women. 11. History of hypersensitivity to lenalidomide (Part B only) 12. History of other active malignancies \< 3 years prior to screening except basal cell carcinoma, low grade Gleason score ≤ 6 prostate cancer that has been removed with undetectable prostate-specific antigen (PSA), and in situ cervical carcinoma.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recommended dose of Phase 2 trial of CWP232291 | up to 4 weeks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cmax as a pharmacokinetic parameter of 'CWP232291' | Predose, 0.25, 0.5, 0.75, 1, 1.5 , 2 , 4 , 8, 12, 24 hours after the start of infusion | Peak plasma concentration(Cmax) of 'CWP232291' |
| AUC as a pharmacokinetic parameter of 'CWP232291' | Predose, 0.25, 0.5, 0.75, 1, 1.5 , 2 , 4 , 8, 12, 24 hours after the start of infusion | Area under the plasma concentration versus time curve (AUC) of 'CWP232291' |
| Cmax as a pharmacokinetic parameter of metabolites of ' CWP232204' | Predose, 0.25, 0.5, 0.75, 1, 1.5 , 2 , 4 , 8, 12, 24 hours after the start of infusion | Peak Plasma Concentration (Cmax) of metabolites of 'CWP232291' |
| AUC as a pharmacokinetic parameter of metabolites of ' CWP232204' | Predose, 0.25, 0.5, 0.75, 1, 1.5 , 2 , 4 , 8, 12, 24 hours after the start of infusion | Area under the plasma concentration versus time curve (AUC) of metabolites of 'CWP232291' |
Countries
South Korea, United States
Outcome results
None listed